Medical Condition News

RSS

Patients can reduce frequency of Botox- Cosmetic injections and still receive same benefits: Research

Patients can decrease the frequency of Botox- Cosmetic injections after approximately two years and still receive most of the same wrinkle-smoothing cosmetic benefits, according to new research at Oregon Health & Science University.

27 Apr 2010

Military trauma transition units breed culture of drug abuse, depression

The New York Times reports on a Warrior Transition Battalion unit in Colorado used by the military to transition injured veterans back into the military or their home lives. "Created in the wake of the scandal in 2007 over serious shortcomings at Walter Reed Army Medical Center, Warrior Transition Units were intended to be sheltering way stations where injured soldiers could recuperate and return to duty or gently process out of the Army.

27 Apr 2010

Mediterranean diet helps reduce risk of cognitive decline in older adults

Findings about what specific components of diets are most beneficial are frequently changing. However, an ongoing study of older adults shows evidence that one type of diet can help mitigate cognitive problems. An ongoing prospective study called the Chicago Health and Aging Project has shown that adherence to the Mediterranean diet can reduce the risk of cognitive decline with older age.

27 Apr 2010

The Women and Heart Disease Summit in Minneapolis

The Minneapolis Heart Institute Foundation, Minneapolis Heart Institute at Abbott Northwestern Hospital, Mayo Clinic, and University of Minnesota are convening The Women and Heart Disease Summit in Minneapolis.

27 Apr 2010

Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting

Cumberland Pharmaceuticals Inc. today announced that results from a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, will be presented at the 2010 Digestive Disease Week meeting in New Orleans.

27 Apr 2010

Phase 2b clinical study initiated to evaluate GI safety of LT-NS001

Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal safety of its investigational drug LT-NS001 (naproxen etemesil). The study will compare the cumulative rate of gastric ulcers vs. Naprosyn after 12 weeks of treatment.

27 Apr 2010

High incidence of MDS among seniors, elderly at increased risk of premature death: Study

Myelodysplastic syndromes - a group of serious blood cancers - are nearly five times more common in seniors than previously thought, according to a new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center.

27 Apr 2010

New report on women's largest cancer challenge: lung cancer

Out of the Shadows: Women and Lung Cancer, a groundbreaking report released today by the Mary Horrigan Connors Center for Women's Health at Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, is a call to action on women's largest cancer challenge: lung cancer.

27 Apr 2010

Phytonutrient intake may help decrease risk for certain chronic diseases: Study

Topping that bowl of cereal with raspberries instead of strawberries, or saut-ing kale instead of spinach for dinner can boost phytonutrient intake, which may help decrease risk for certain chronic diseases, including cardiovascular disease, cancer and diabetes.

27 Apr 2010

Nearly 50% of adult U.S. population at risk from heart disease

The U.S. Centers for Disease Control (CDC) released an alarming new report on Monday. According to the CDC report almost 50% of the adult population of the United States have chronic conditions which could lead to heart disease. The pre-existing diagnosed conditions included high blood pressure, high cholesterol and diabetes.

27 Apr 2010

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.

27 Apr 2010

Factors of hormone metabolism may make African-Americans more susceptible: Study

High blood pressure also called hypertension is a major health problem that when left untreated can lead to heart disease, stroke and kidney failure. African Americans are more likely to develop high blood pressure and develop it earlier in life than Caucasians. But the reasons for the heightened risk in African Americans still remained largely unknown, although new evidence may provide some insight.

26 Apr 2010

Popular antidepressants may have beneficial side effects for cardiovascular health: Study

A class of antidepressants known as selective serotonin reuptake inhibitors may provide a boost to cardiovascular health by affecting the way platelets, small cells in the blood involved in clotting, clump together, say researchers at the Loyola University Medical Center in Maywood, Ill.

26 Apr 2010

Comprehensive book on reconstructive techniques for degenerative mitral valve disease

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, proudly announces the release of a brand-new single volume comprehensive book on reconstructive techniques for degenerative mitral valve disease by the internationally renowned cardiac surgeon and educator, Dr. Alain Carpentier. The book will launch at the 90th Annual Meeting of the American Association for Thoracic Surgery at the Metro Toronto Convention Centre in Toronto, Ontario, Canada, May 1 - 5, 2010.

26 Apr 2010

ERCC1 Analysis guides patient treatment decisions

Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

26 Apr 2010

New syndicated report covers the use of DMAs for treatment of MS published

BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends: Multiple Sclerosis. This report covers the use of disease-modifying agents for the treatment of multiple sclerosis, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth and expected future use.

26 Apr 2010

Exercise helps retain greater bone density: Researchers

The stage for osteoporosis is set well before menopause-but exercise can help rewrite the script, according to Medical College of Georgia researchers.

26 Apr 2010

Caltech biologists offer new insight into causes of IBD and colon cancer

We are not alone-even in our own bodies. The human gut is home to 100 trillion bacteria, which, for millions of years, have co-evolved along with our digestive and immune systems. Most people view bacteria as harmful pathogens that cause infections and disease. Other, more agreeable, microbes (known as symbionts) have taken a different evolutionary path, and have established beneficial relationships with their hosts.

26 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

American board-certified prosthetist develops custom-made ankle-foot orthosis

With over ten million diabetics in the U.S. alone and approximately 150,000 amputations performed yearly, inventor and American board-certified prosthetist John E. Rooney developed a custom-made ankle-foot orthosis with the trade name Ulcer Healing Orthosis or UHO.

26 Apr 2010